Kedudukan dalam Saham
#34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Harga Saham
$0.6379482
Disegerakkan terakhir: 2023-05-22
Perubahan (1 hari)
-0.44%
Perubahan (1 tahun)
0.00%
Perdagangan Nicox S.A. (COX)
Harga COX dengan permodalan pasaran b
Modal pasaran bagi Nicox S.A.(COX)
Modal Pasaran: $5.98M
Sehingga August 2026, Nicox S.A. mempunyai modal pasaran sebanyak $5.98M. Ini menjadikan Nicox S.A. syarikat ke-34243rd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Nicox S.A. dari 2000 hingga 2026
COX berbanding dengan 5 teratas yang paling popular stocks
| Harga COX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+91,209,925.47%
|
|
|
|
|
$4.490T
|
+75,118,166.62%
|
|
|
|
|
$4.162T
|
+69,637,181.89%
|
|
|
|
|
$3.676T
|
+61,505,296.67%
|
|
|
|
|
$2.833T
|
+47,396,847.74%
|
